| 标题 |
专利、报告等 Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
|
| 网址 | |
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 | 是发表在2022年ASCO大会上的,应该是个PPT |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)